At RANZCO 2025, Dr. Mark Chiang rethinks the old “drops first” reflex in light of today’s laser options. He explains how more patients are arriving already aware of SLT-first evidence, how he frames its 20–30% pressure reduction, and why ocular surface health and future surgical outcomes often push him toward laser over long-term topical therapy.
He then maps out where SubCyclo fits alongside SLT and microbypass stents: a pulsed, tissue-sparing option for patients who fail or cannot tolerate earlier steps, or who are not ideal candidates for incisional surgery. With SLT, SubCyclo and thermocyclo all available in one clinic, he can cover mild, moderate and refractory glaucoma with a coherent, laser-based plan instead of relying on bottles alone.
See how this fits into your own practice at https://www.lumibird.com/en/.
This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.
